The company said it will use the money, which is an extension of a $26.5 million Series B round completed in May 2010, to advance and expand research, development, and validation of protein biomarker-based laboratory tests.
Janssen becomes the third assay content provider for Biocartis' integrated "sample-to-answer" nucleic acid testing platform as the company drives toward a full commercial launch in the second half of 2012.
Janssen and J&J's Ortho-Clinical Diagnostics group have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.
The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.
While the use of sequencing in disease research for both Mendelian and complex diseases continued to advance during the year, 2010 also saw the launch of several sequencing-based diagnostic tests, as well as pharmaceutical companies entering the sequencing field and the first examples of sequencing being used to make decisions on patient treatment.
Instead of focusing on whole-genome sequencing, which they all said was still too expensive, the three pharma companies are focusing on either specific genes, a portion of the exome, or the transcriptome.
SpeeDx, a spinout of Johnson & Johnson's Australian research subsidiary, claims its multi-component nucleic acid enzymes, or MNAzymes, provide significant advantages over current enzymes for multiplex qPCR applications.